Keyphrases
Motor Deficits
100%
Ropinirole
100%
Common Marmoset
100%
Dyskinesia
100%
Continuous Delivery
100%
Continuous Infusion
50%
Locomotor Activity
37%
Oral Administration
37%
Motor Impairment
37%
Dopamine Agonist
25%
Continuous Drug Delivery
12%
Motor Complications
12%
Subcutaneous Infusion
12%
Controlled Release Formulation
12%
Continuous Dopaminergic Stimulation
12%
Osmotic Minipump
12%
Once-daily
12%
Treatment Group
12%
Parkinson's Disease
12%
Drug Levels
12%
High Incidence
12%
L-DOPA
12%
Continuous Treatment
12%
Parkinson Patients
12%
Pharmacology, Toxicology and Pharmaceutical Science
Dyskinesia
100%
Ropinirole
100%
Mitochondrial Permeability Transition Pore
100%
1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine
100%
Callithrix jacchus
100%
Dopamine Receptor Stimulating Agent
37%
Motor Dysfunction
37%
Parkinson's Disease
25%
Subcutaneous Injection
12%
Controlled Release Formulation
12%
DOPA
12%
Neuroscience
Mitochondrial Permeability Transition Pore
100%
Dyskinesia
100%
Ropinirole
100%
Locomotor Activity
37%
Stereotypic Movement Disorder
37%
Dopamine Agonist
25%
Parkinson's Disease
12%
Blood Plasma
12%
L-DOPA
12%
Dopaminergic
12%
Treatment of Parkinson's Disease
12%